By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Piper Jaffray today initiated coverage of Meridian Bioscience with an Underweight rating, saying that its nascent molecular diagnostics business faces multiple challenges from competitors.

The investment bank gave Meridian a $14 target price on its stock, and estimated 2011 sales at $159.8 million, resulting in net earnings of $28.5 million, or $.69 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.